→ Bear market expert makes new prediction (From Legacy Research)
Encompass Health Co. (NYSE:EHC – Get Rating) – William Blair cut their Q3 2024 earnings estimates for Encompass Health in a research report issued on Monday, April 3rd. William Blair analyst M. Larew now forecasts that the company will post earnings of $0.89 per share for the quarter, down from their prior forecast of $0.99. The consensus estimate for Encompass Health’s current full-year earnings is $3.07 per share. William Blair also issued estimates for Encompass Health’s Q4 2024 earnings at $0.99 EPS.
Several other research firms also recently commented on EHC. Truist Financial increased their target price on shares of Encompass Health from $70.00 to $75.00 and gave the stock a “buy” rating in a research report on Thursday, February 9th. Mizuho raised their price objective on Encompass Health from $65.00 to $69.00 and gave the company a “buy” rating in a research note on Thursday, February 9th. StockNews.com started coverage on Encompass Health in a research report on Thursday, March 16th. They set a “hold” rating for the company. Credit Suisse Group increased their price target on Encompass Health from $62.00 to $73.00 and gave the company an “outperform” rating in a report on Thursday, February 9th. Finally, Stephens restated an “overweight” rating and issued a $70.00 price objective on shares of Encompass Health in a research note on Wednesday, February 8th. Two investment analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, Encompass Health currently has a consensus rating of “Moderate Buy” and an average target price of $69.40.
Encompass Health Stock Performance
Shares of EHC opened at $60.07 on Wednesday. The company has a quick ratio of 1.25, a current ratio of 1.25 and a debt-to-equity ratio of 1.50. Encompass Health has a 12 month low of $44.33 and a 12 month high of $74.61. The company’s fifty day moving average is $57.48 and its 200-day moving average is $55.76. The firm has a market cap of $5.99 billion, a price-to-earnings ratio of 22.25, a price-to-earnings-growth ratio of 1.26 and a beta of 1.05.
Institutional Investors Weigh In On Encompass Health
Several institutional investors and hedge funds have recently bought and sold shares of the business. Lazard Asset Management LLC boosted its position in shares of Encompass Health by 14.3% during the 4th quarter. Lazard Asset Management LLC now owns 1,290 shares of the company’s stock valued at $77,000 after acquiring an additional 161 shares in the last quarter. Bank of Montreal Can lifted its stake in Encompass Health by 1.5% during the first quarter. Bank of Montreal Can now owns 11,340 shares of the company’s stock worth $806,000 after purchasing an additional 173 shares during the period. Commonwealth Equity Services LLC boosted its holdings in Encompass Health by 3.9% during the fourth quarter. Commonwealth Equity Services LLC now owns 4,692 shares of the company’s stock valued at $280,000 after purchasing an additional 174 shares in the last quarter. Horrell Capital Management Inc. grew its stake in shares of Encompass Health by 0.6% in the 4th quarter. Horrell Capital Management Inc. now owns 29,330 shares of the company’s stock valued at $1,754,000 after purchasing an additional 185 shares during the period. Finally, Louisiana State Employees Retirement System raised its holdings in shares of Encompass Health by 0.8% in the 4th quarter. Louisiana State Employees Retirement System now owns 26,700 shares of the company’s stock worth $1,597,000 after buying an additional 200 shares in the last quarter. Institutional investors own 96.14% of the company’s stock.
Insider Activity at Encompass Health
In other Encompass Health news, CFO Douglas E. Coltharp sold 17,895 shares of the firm’s stock in a transaction that occurred on Friday, February 10th. The stock was sold at an average price of $60.78, for a total value of $1,087,658.10. Following the completion of the sale, the chief financial officer now owns 53,097 shares in the company, valued at approximately $3,227,235.66. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 2.70% of the company’s stock.
Encompass Health Dividend Announcement
The business also recently announced a quarterly dividend, which will be paid on Monday, April 17th. Investors of record on Monday, April 3rd will be paid a $0.15 dividend. This represents a $0.60 annualized dividend and a dividend yield of 1.00%. The ex-dividend date of this dividend is Friday, March 31st. Encompass Health’s payout ratio is presently 22.22%.
Encompass Health Company Profile
Encompass Health Corp. engages in the provision of post-acute healthcare services. It operates through the Inpatient Rehabilitation and Home Health and Hospice segments. The Inpatient Rehabilitation segment operates inpatient rehabilitation hospitals that provide rehabilitative treatment and care to patients who are recovering from stroke and other neurological disorders, cardiac and pulmonary conditions, brain and spinal cord injuries, complex orthopedic conditions and amputations.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Encompass Health, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Encompass Health wasn’t on the list.
While Encompass Health currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
Source: marketbeat.com
